A fixed-dose combination topical preparation containing an antifungal (Terbinafine), a potent corticosteroid (Clobetasol), a fluoroquinolone antibiotic (Ofloxacin), and a nitroimidazole antibiotic (Ornidazole). It is designed for the treatment of complex, mixed, or secondarily infected inflammatory fungal skin conditions, commonly seen in the Indian tropical climate. It addresses infection, inflammation, and pruritus simultaneously.
Adult: Apply a thin film to the affected area twice daily, or as directed by the physician. Duration: Usually for 1-2 weeks. Do not exceed 2 weeks of continuous use.
Note: 1. Wash and dry the affected area thoroughly. 2. Take a small amount of cream on clean fingertips. 3. Apply a thin layer and rub gently until absorbed. 4. Wash hands after application unless hands are the treatment area. 5. Do not cover with occlusive dressings unless advised. 6. Avoid contact with eyes, nose, mouth, and mucous membranes.
This combination exerts a multi-pronged action: 1) Terbinafine inhibits fungal squalene epoxidase, leading to ergosterol depletion and fungal cell death. 2) Clobetasol, a super-potent corticosteroid, induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, thereby suppressing inflammation, vasoconstriction, and pruritus. 3) Ofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, causing bactericidal effect. 4) Ornidazole undergoes intracellular reduction of its nitro group, generating toxic intermediates that damage microbial DNA, leading to cell death in anaerobic bacteria and protozoa.
Pregnancy: Category C (US FDA). All components cross the placenta. Terbinafine and Ornidazole are contraindicated in pregnancy. Clobetasol is teratogenic in animals. Ofloxacin may cause arthropathy in immature animals. This combination is NOT recommended during pregnancy. Use only if potential benefit justifies potential fetal risk, and for minimal duration on small areas.
Driving: Generally safe. However, if systemic absorption causes CNS effects like dizziness, headache (from Ornidazole/Ofloxacin), patients should be cautioned about driving or operating machinery.
| Other Topical Corticosteroids | Additive risk of skin atrophy and systemic absorption. | Major |
| Systemic Corticosteroids (e.g., Prednisolone) | Increased risk of HPA axis suppression and Cushingoid features. | Major |
| Warfarin | Ornidazole may inhibit metabolism, increasing INR and bleeding risk. | Moderate |
| Theophylline | Ofloxacin may increase theophylline levels (CYP1A2 inhibition). | Moderate |
| Alcohol | Disulfiram-like reaction with Ornidazole (flushing, tachycardia, nausea). | Moderate |
| CYP2C9 Substrates (e.g., Phenytoin, NSAIDs) | Terbinafine is a potent inhibitor; may increase their levels. | Moderate |
| QT-prolonging drugs (e.g., Erythromycin, Antiarrhythmics) | Ofloxacin may have additive effect on QT interval. | Moderate |
Same composition (Terbinafine (NA) + Clobetasol (NA) + Ofloxacin (NA) + Ornidazole (NA)), different brands: